Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Polyphor Ltd.
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02096315CT.gov Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis. | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bronchiectasis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Murepavadin (this asset) | Polyphor Ltd. | P2 | CCC · 53 |
| Ciprofloxacin | Centre Hospitalier Intercommunal Creteil | P4 | BBB |
| Azithromycin | Assiut University | P4 | BBB |
| Atorvastatin | University of Edinburgh | P4 | BB |
| Roflumilast | The University of Hong Kong | P3 | BB |
| Theophylline | The First Affiliated Hospital of Guangzhou Medical University | P4 | BB |
| Colistimethate | Centre Hospitalier Intercommunal Creteil | P3 | BB |
| Aztreonam Lysine | Gilead Sciences | P3 | BB |
| Tazobactam | Sunshine Coast Hospital and Health Service | P4 | BB |
+42 more in the Bronchiectasis cohort
Other indications for Murepavadin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Respiratory Tract Infectious Disorder | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Murepavadin in Bronchiectasis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/murepavadin-bronchiectasis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →